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An update on the safety of CNS stimulants for the treatment of ADHD 
 







Introduction: Methylphenidate is the first-line pharmacological treatment of attention-
deficit/hyperactivity disorder (ADHD). Although methylphenidate has a well-established 
evidence base for treating ADHD, its long-term benefits are unclear. 
Areas covered: Physical adverse effects, psychiatric adverse events and brain development 
Expert opinion: Some physical adverse events have been described (e.g. sleep disturbances, 
growth reduction, loss of appetite), although most are of transient nature. Psychiatric adverse 
events seem more related to the diagnosis ADHD itself, and not stimulant treatment. 
Concluding, short-to-mid-term use (i.e., up to 2 years) stimulants are relatively safe, but much 
less is known about longer-term efficacy and safety of these drugs. 
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1. Introduction  
 
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
characterized by age-inappropriate symptoms of inattention, hyperactivity, and impulsivity 
[1]. ADHD affects around 3 to 4% of children and adolescents [2] and often continues into 
adulthood [3] with rates in adulthood varying around 2.5% [4]. Stimulant medication such as 
methylphenidate and dexamphetamine form the first-line pharmacological treatment of 
ADHD [5]. Stimulants increase the synaptic availability of dopamine [6]. Although the short-
term evidence base of stimulants is well-established [7, 8], its long term benefits are still 
unclear [9]. While serious adverse events are very rare, common adverse effects include sleep 
disturbances [10], loss of appetite and reduced growth [11]. Other concerns regarding 
stimulants include their possible effects on cardiovascular health and on brain development, 
and their risk of inducing other psychiatric problems. 
 
While the majority of studies assessing the safety of methylphenidate have been performed in 
children or adolescents, dosing and adverse effects of methylphenidate in adults are very 
similar to those reported in pediatric samples: in an open-label flexible dose study of OROS 
methylphenidate for the treatment of adults with ADHD (N =370), adverse events were 
reported in 68% of patients and most were mild or moderate in severity; most frequently 
reported included headache (17%), decreased appetite (13%), and insomnia (11%) [12]. Small 
mean increases in systolic and diastolic blood pressure (both 2.4 mmHg) and pulse (3.2 bpm) 
were observed. Body weight decreased slightly (-1.5 kg). Medication was adjusted to 
optimize efficacy and tolerability for each patient. Furthermore, adverse events, vital signs, 
and laboratory parameters were assessed. The final dispensed doses were 18 mg (8%), 36 mg 
(29%), 54 mg (34%), 72 mg (20%), or 90 mg (9%). Thus there are no marked differences 
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between adult and pediatric samples concerning adverse events and dose. 
In this narrative review we have summarized relevant and recent literature about adverse 
physical and psychiatric events following stimulant treatment in individuals with ADHD.  
 
2. Adverse physical events 
 
2.1. Growth.  
 
Stimulant treatment has repeatedly been associated with reduced growth [11], potentially due 
to treatment-induced loss of appetite [13]. Alternatively, increases in synaptic dopamine may 
reduce the secretion of growth hormone, which in turn may lead to a reduction in growth [14]. 
However, a longitudinal study found no effect of stimulant treatment on growth hormone 
secretion [15].  
 
Although effects on growth have generally been minor [16], large variability in those affected 
has been described [17]. Interestingly, in adulthood there is no difference in height between 
those who have or have not been treated with stimulants in their youth [18]. This observation 
has resulted in two mechanistic theories about the effects of stimulants on growth. The 
delayed growth theory states that, after initial slowing of growth in those treated with 
stimulants, growth rates return to normal with continued use. The second theory states that 
discontinuing use, for example during drug holidays, will lower the risk of growth deficits. As 
stated in the review by Faraone, there is evidence supporting both mechanisms. Taking drug 
holidays does not resolve the growth deficit [19], possibly because a six-week period is not 
sufficiently long to catch-up on a full year of growth. Thus, while many studies have been 
performed on this topic, at this moment no consensus exists on the exact mechanism 
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underlying stimulant-induced growth reduction. Trouble with these studies is that they were 
mostly done retrospectively or did not have a sufficiently long enough follow-up period, and 
did not use a detailed report of pharmacological history. 
 
The European Guidelines Group advises adequate monitoring of children’s weight and height 
using growth charts every six months during treatment. If concerns arise, a first focus should 
be on improving nutrition [16]. While drug holidays seem the obvious option, these should be 
applied with caution. Drug holidays can put a strain on families with ADHD because 
symptoms may reemerge and may temporarily worsen.  
 
2.2. Cardiovascular health. 
 
Stimulants have long been regarded as drugs with a low probability of serious cardiovascular 
events. Mild elevations of heart rate and blood pressure after stimulant administration have 
been well documented, resulting from the sympathomimetic effects of these drugs. Early on, 
this has prompted recommendations for appropriate monitoring of cardiovascular function in 
stimulant users and assessing the personal and familial history of cardiovascular diseases [20, 
21]. In recent years, incidental reports of sudden cardiac death in treated children have fueled 
major concerns about the safety of stimulant treatment amongst professionals, policy makers, 
and the general public [22]. These concerns are strengthened by the increased prevalence and 
duration of stimulant use in children and adults with ADHD symptoms [23]. Indeed, many 
experts express their caution as the long-term effects of stimulant use (i.e., > two years) on 
cardiovascular health are not yet fully known, which might pose a particular threat in 
individuals at risk for cardiovascular disease or with a known condition [20, 21, 22, 24]. As a 
consequence, in recent years a growing number of meta-analytic and systematic reviews on 
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the role of stimulants for cardiovascular health have been published. Moreover, the number of 
high-quality studies including large population-based samples or randomized placebo-
controlled clinical trials is mounting. Obviously, low sample sizes are a threat for 
underestimating risk of serious events of stimulant users, given their low prevalence in the 
general population.  
 
Mazza and colleagues [25] conducted a meta-analysis of three large observational studies in 
mostly young individuals with ADHD currently using stimulants for more than one year. The 
authors reported no increased risk of sudden cardiac death or stroke in this group. Their meta-
analysis included 806,162 person-years (498,556–1,663,560), showing rates of 10.5/100,000 
person-years (4.4–16.5) of sudden death and 14.13/100,000 person-years (5.88–22.37) of 
stroke. At least ten large population-based studies in both children and adolescents as well as 
adults are now available [e.g., reviewed in 22, 26] with over > 5,000,000 observed patient-
years [27]. These studies are mostly based on retrospective reports [28, 29, 30] derived from 
various sources, such as U.S. state and federal death registries and databases of U.S. insurance 
claims or UK general practitioners. Reviews have concluded that sudden death or other 
serious adverse events (e.g., myocardial infarction, stroke, ventricular arrhythmia, all-cause 
mortality) are extremely rare amongst stimulant users and do not appear to occur beyond the 
risk of non-users in the general population [20, 21, 22, 31, 32, 33]. Studies with a mean 
duration of 2.1 years of follow-up in children and adolescents and a mean duration of 0.33 
years of current use in adults [21, 29] pointed to encouraging safety with respect to the short- 
and medium-term use of stimulants. 
 
Another available meta-analysis based on ten adult controlled trials reported an increased 
resting heart rate [+5.7bpm (3.6,7.8)] and systolic blood pressure [+2.0mmHg (0.8,3.2)] 
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associated with stimulant use in adults [24]. These subtle elevations (heart rate ≤ 10 bpm, 
blood pressure ≤ 5 mmHg), which are not considered clinically relevant, are in line with the 
more extensive child literature on stimulant use in ADHD [20, 31]. Also, to date, there is no 
evidence for deviations in electrocardiographic parameters such as prolonged QTc interval 
[20, 24, 31].  
 
Critical notes have been expressed as well, pointing to methodological issues (e.g., 
insufficient control of confounding, selection bias, incomplete medical records, unknown 
influence of time and dose effects) and still underpowered studies in both child and adult 
populations [21, 26]. These issues may have contributed to false negative findings, although 
methodological flaws have also been pointed out in studies reporting increased cardiovascular 
risks [34, 35, 36], as discussed by various authors [20, 22, 26, 27, 37]. Although Schelleman 
[30] found an 1.8-fold increased risk of sudden death or ventricular arrhythmia in stimulant 
users versus non-users, the authors concluded that there was no causal link between stimulant 
use and cardiovascular risk, given that dose was inversely related to this risk.  
 
To conclude, current evidence on the cardiovascular safety of stimulant use in children, 
adolescents, and adults with ADHD symptoms is encouraging for the short- and medium-term 
use (< two years), with an extremely low risk of serious cardiovascular events. Several 
important challenges need to be addressed in future research. Studies of long-term exposure to 
stimulants (> two years) are rare and therefore highly needed [38], which will require very 
large, sufficiently powered population-based databases, and will have to overcome 
methodological criticisms [26]. In particular, there is a need to assess the potential long-term 
effects of the stimulant-induced increase in heart rate and blood pressure, taking into account 
that cardiovascular function varies with age. The sympathetic effects of stimulants may 
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possibly predispose certain users to serious cardiovascular problems on the longer term or 
lead to pathological changes over time [20, 25]. For example, the Multimodal Treatment 
Study of Children with ADHD (MTA) found increased heart rate at 10-year follow-up [see 
21, 39]. Moreover, risk-assessment in vulnerable individuals is needed, for example in those 
with (pre)hypertension, metabolic syndrome, or other cardiovascular conditions [32], as well 
as in those with a familial history of cardiovascular disease. Studies in these areas are still 
sparse and current research has often selected on healthy ADHD subjects without known pre-
existing cardiovascular problems. Finally, more attention should be drawn to stimulant use in 
adults, as adults are still underrepresented in the current literature, yet are more likely to show 
signs of cardiovascular wear and tear due to aging. Before we can rule out long-term 
cardiovascular risks of stimulant use in vulnerable and non-vulnerable subjects, more high 
quality, long-term research needs to be conducted, for example, by using data from 
nationwide birth cohorts and joining forces across large prospective population-based studies 
around the globe.  
 
2.3. Seizures.  
 
While the summary of product characteristics states that methylphenidate should be used with 
caution in patients with epilepsy and that it may lower the convulsive threshold in patients 
with a prior history of seizures, this warning is not actually justified by research findings. A 
recent systematic review identified seven prospective studies and two retrospective studies, 
and  none of these studies reported higher seizure rates after exposure to methylphenidate 
[40]. Moreover, methylphenidate is also effective for the treatment of ADHD symptoms in 








The presence of a tic disorder and even a family history of tic disorders is a contraindication 
for the use of methylphenidate according to the United States Food and Drug Administration. 
This warning reflects worries that methylphenidate may evoke tics in susceptible individuals 
(i.e., those with a family history) and may exacerbate tics in those with existing tics. 
However, these contraindications stem from anecdotal reports but are not backed by a recent 
meta-analysis [43]. One of the first case reports describing a possible link of methylphenidate 
treatment with the subsequent development of tics appeared over 40 years ago [44]. A nine-
year-old boy then described as having clinically typical ‘minimal brain dysfunction’ 
developed Tourette syndrome eight weeks after the start of therapy with methylphenidate with 
tics persisting after methylphenidate was discontinued. More case reports described the onset 
of tics after the initiation of methylphenidate therapy [45, 46, 47] along with case reports in 
which exacerbation of tics after the use of methylphenidate in children with pre-existing 
Tourette syndrome were described [48]. However, in a large case series involving 1520 
children, tics developed in only 14 children and became worse in only six children with pre-
existing tics after methylphenidate administration [49]. Subsequent authors challenged the 
causal link between methylphenidate and the provocation or exacerbation of tics and 
concluded that there is virtually no evidence that stimulants may cause or exacerbate tics [50]. 
This was confirmed in small controlled studies investigating the effects of varying doses of 
methylphenidate in children with a tic disorder, with none of the doses leading to an increase 
in tics [51, 52, 53]. Others, though, continued to note that methylphenidate may increase the 
severity of tics in a portion of patients with Tourette syndrome [44, 54, 55]. However, a 
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blinded placebo-controlled cross-over study reported relatively high rates of tic onsets or 
exacerbations, but no differences between the placebo and methylphenidate condition were 
seen [56]. Another placebo-controlled study confirmed that the proportion of individual 
subjects with Tourette syndrome reporting a worsening of tics was no higher in those treated 
with methylphenidate than those being administered placebo [57]. Pooled data from three 
placebo-controlled studies also showed that the incidence of tics was not significantly 
different across those treated with osmotic-controlled release oral delivery system (OROS) 
methylphenidate, short acting methylphenidate, or placebo [58]. Finally, a recent meta-
analysis of 22 controlled trials involving 2,385 children [43] seems to have settled the issue its 
results did not support an association between new onset or worsening of tics and use of 
psychostimulants, with these events being similarly reported in the stimulant (event rate = 
5.7%, 95% CI = 3.7%-8.6%) and placebo groups (event rate = 6.5%, 95% CI = 4.4%-9.5%). 
In conclusion, despite the official Food and Drug Administration’s contraindication and 
despite the official Food and Drug administration’s contraindication and despite previous 
concerns in the literature methylphenidate does not appear to pose a risk for the development 
or exacerbation of tics. When such events do occur in a child, these symptoms are much more 
likely to be coincidental rather than caused by methylphenidate. 
 
3.2. Psychotic events. 
 
As methylphenidate enhances the synaptic availability of dopamine it might be expected to 
pose a risk factor for psychotic episodes. Indeed, a number of case studies have described the 
onset of psychotic features in children prescribed methylphenidate [59, 60, 61]. Moreover, in 
a high-risk cohort of children of whom one or both parents were affected with major 
depressive disorder, bipolar disorder, or schizophrenia, 62.5% of those who had taken 
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stimulants had psychotic symptoms, compared with 27.4% in those who had never taken 
stimulants. Moreover, in cases that were assessed both on and off stimulants, there was an 
association between current stimulant use and concurrent psychotic symptoms, supporting a 
temporal relationship between use of stimulants and psychotic symptoms [62]. Furthermore, 
in a cohort of individuals who had developed psychotic disorders, the age of onset of 
psychosis was significantly lower in those previously exposed to stimulants [20.5 vs. 24.6 
years stimulants vs. no stimulants; 63]. In another large-scale cohort study of individuals who 
were newly diagnosed with ADHD, methylphenidate use significantly increased the risk of 
developing any psychotic disorder except schizophrenia [64]. There have been no trials 
investigating psychopharmacological treatment of patients with schizophrenia and ADHD. 
These observations suggest a relationship between methylphenidate treatment and the onset of 
psychotic events. In contrast, a well-designed, large-scale study, involving 20,586 individuals 
did not support this, but indicated an increased risk of psychotic events before but not during 
prescription of methylphenidate. This points to an association of psychotic events with 
ADHD symptoms rather than with methylphenidate [65]. Thus it is likely that previous study 
results suggesting a link between methylphenidate use and psychotic events may be partially 
explained by ADHD being a risk factor for the later development of psychotic disorders [66], 
and that the link between methylphenidate and psychotic events may be limited to transient 
psychosis in susceptible individuals. 
 
3.3. Mood problems and suicidality 
 
While individuals with ADHD have an increased risk of developing a depressive or bipolar 
disorder, longer treatment with methylphenidate has actually been demonstrated to protect 
against these disorders [67, 68]. However, bipolar disorder and ADHD show a high degree of 
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symptom overlap and comorbidity. Clinical trials and case reports indicate that 
psychostimulants do not or only rarely trigger or aggravate manic episodes and can even 
produce rapid and pronounced antimanic effects [69]. Other studies have also pointed out that 
methylphenidate may improve mood problems [70]. Moreover, a large-scale registry based 
longitudinal study found no evidence for a positive association between the use of 
methylphenidate and the risk of concomitant suicidal behavior among individuals with 
ADHD. If anything, the results pointed to a potential protective effect of methylphenidate on 
suicidal behavior [71].  
 
A common worry, however, of parents is that treatment with methylphenidate may lead to 
dampening of spontaneity and/or a flat affect. So far, perceived adverse events of 
methylphenidate on cognition (such as reasoning, depth/breadth of thinking, intellectual 
capacity, and creativity), motivation (e.g., drive, effort, and attitudes toward 
rewards/incentives) and mood (e.g., dampening of spontaneity/flat affect, mood 
dysregulation, increased anxiety/edginess) have not been systematically assessed. A recent 
study used a qualitative semi-structured interview to capture such adverse events of 
methylphenidate. This has led to the development of a new questionnaire that can be used for 
monitoring such events in medication trials or routine clinical care [72]. This new instrument 
is certainly very welcome given the scarcity of data in this area.  
 
3.4. Substance-related disorders. 
 
Individuals with ADHD are at increased risk of developing substance-related disorders and 
nicotine dependence [73]. Despite great research investments, the mechanisms underlying this 
increased risk remain unclear. Worries have been voiced that treating ADHD with stimulants 
 
 13 
increases the risk of developing substance-related disorders later in life and that treatment 
with stimulants may aggravate substance misuse in those individuals with co-occurring 
substance-related disorders and ADHD.  
 
Seeing that stimulants have the potential to be addictive, professionals and parents have been 
concerned that stimulant treatment may have a negative effect on the development of 
substance use disorders (SUDs) in ADHD [74]. These concerns are mainly based on the 
sensitization hypothesis, stating that exposure to stimulants may increase substance abuse by 
increasing the sensitivity to the reinforcing effects of previously experienced drugs (i.e., 
stimulant treatment). This, in turn, may result in a higher risk of developing substance-related 
disorders and nicotine dependence. Only one study in humans has found an increased risk of 
smoking and cocaine use in those previously treated with stimulants, but possibly results of 
these studies were confounded by higher comorbidities in the stimulant group [75]. Two well-
performed recent meta-analyses of prospective studies have further invalidated these 
concerns. While one meta-analysis reported a protective effect of stimulant treatment on the 
development of tobacco use [76], the other found that stimulant treatment did not affect the 
development of substance use disorder or nicotine dependence [77]. These inconsistent results 
may be due to differences in outcome measure severity (i.e. tobacco use vs. nicotine 
dependence), but also due to unknown underlying moderators. Factors that might enhance the 
protective effects of stimulant treatment on substance-related disorders include an earlier 
onset of stimulant use [78, 79] and longer duration of stimulant use [79, 80]. Note that other 
studies did not replicate these findings [e.g., 81]. However, the evidence for a protective 
effect of characteristics of stimulant use is scarce, and the interaction between these factors 
has not been described. Interestingly, one study found an increased risk of substance-related 
disorders in those individuals with who had only used nonstimulant medication [79].  
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Summarizing, the evidence suggests that treating ADHD in childhood with stimulants does 
not increase the risk of developing substance-related disorders later in life, but further 
research into the mechanisms of a possible protective effect of stimulants on the later 
development is warranted.  
 
Among those suffering from substance-related disorders, the prevalence of ADHD is high 
[23.1%;82]. Treatment in these individuals already suffering from substance-related disorders 
is an area of concern. The main concern is misuse of stimulant medication. Immediate release 
stimulants have a higher potential of misuse than long acting stimulants [83]. The most 
common methods of misuse of immediate release stimulants are intranasal (“snorting”) or 
injection of crushed tablets [84]. The second area of concern is the efficacy of ADHD 
treatment. Little research has been performed on the efficacy in of pharmacological 
interventions for co-occurring ADHD and substance-related disorders. The studies that have 
been done, show an improvement in ADHD symptoms, but not substance-related disorders 
[85]. According to the self-medication theory, individuals with ADHD use drugs of abuse to 
reduce their ADHD symptoms. Following this reasoning, one can assume that a reduction in 
ADHD symptoms (due to pharmacological treatment) would lead to a reduction in substance-
related behaviors. However, no evidence for this has been found [85]. Furthermore, the use of 
stimulants in combination with alcohol or drugs only mildly increases the number of side 
effects experienced [86]. Guidelines typically advice abstinence before commencing 
pharmacological treatment of ADHD, prescription of drugs with lower misuse potential (e.g. 
atomoxetine, or long-acting stimulants), and/or close monitoring by a trained professional [5]. 
In sum, stimulant treatment of co-occurring ADHD and substance-related disorders is 
effective in treating symptoms of ADHD, but not substance use severity. However, due to the 
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misuse potential of short acting formulations, caution should be taken in prescribing these 
formulations.  
 
Stimulant treatment of ADHD early in life does not seem to impose a risk for the later 
development of substance-related disorders. Certain characteristics of medication use (e.g. 
longer duration of use, younger onset age) may induce a protective effect on the later 
development of substance use problems, but more research is warranted to elucidate these 
complex issues. Regarding pharmacological treatment of adolescents and adults with co-
occurring ADHD and substance-related disorders, caution is warranted. Concerns are mainly 




A 60% increase in the number of sleep disturbances is reported after the use of stimulant 
treatment [13]. This can have a great impact on quality of life [87]. Complicating this 
relationship are findings that medication naive children with ADHD experience sleep 
problems as well [88], but also findings that show sleep problems can aggravate symptoms of 
ADHD and comorbid disorders [89], and even suggestions that sleep problems are at the base 
of ADHD [90]. Despite these complexities, it is likely that sleep disturbances are already 
present in children with ADHD, and that stimulant treatment can aggravate these problems. A 
recent meta-analysis showed that stimulant medication leads to a longer sleep latency, worse 
sleep efficiency, and shorter sleep duration [91]. Dose effects have been found on sleep 
latency and sleep duration [92]. Frequency of the dose also moderated sleep latency [91], 
although this could reflect the effect of immediate release versus extended release formulas. 
Overall, there are indications that sleep disturbances can emerge due to stimulant treatment. 
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Moreover, it has been suggested that there is a genetic vulnerability (i.e. carriers of 10/10 
DAT1 genotype) to somatic adverse events, such as sleep disturbances. However, more 
research is warranted to elucidate working mechanisms concerning this important issue. 
The European guidelines group recommends that sleep analyses is done before initiating 
stimulant treatment. If sleep problems persist or intensify after stimulant treatment, one may 
consider switching to non-stimulant medication [16] or a long-acting stimulant with a shorter 
duration. Behavioral interventions have been shown efficacious in treating insomnia in 
children with ADHD [93]. 
 
4. Brain development 
 
4.1. Structural and functional magnetic resonance imaging 
 
Concerns that stimulant treatment may adversely affect brain development are frequently 
voiced. Evidence for stimulant-induced damage to dopaminergic nerve terminals stems 
almost exclusively from animal studies, in which stimulants are typically administered in 
binge-like patterns at high dosages. To investigate the effects of stimulant treatment in 
humans, most researchers resort to magnetic resonance imaging (MRI) that provides indirect 
measurements of brain structure and function.  
 
Several structural MRI studies have suggested that long-term stimulant treatment may result 
in normalization of brain structure, although findings have been mixed. Two meta-analyses 
reported indirect evidence that stimulant treatment is associated with more normative basal 
ganglia volumes: across studies, findings of caudate nucleus and putamen volume reduction 
were more pronounced when predominantly medication-naïve individuals were included, as 
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compared to when more previously treated individuals were included [94, 95]. However, 
large-scale studies failed to detect volumetric differences in the striatum between treated and 
untreated patients, or associations between treatment duration and striatal volumes [96, 97, 
98, 99, 100, 101]. In other brain regions, including the lateral prefrontal cortex, anterior 
cingulate cortex, thalamus, and cerebellum, treatment effects suggestive of normalization 
have been reported [98, 102, 103, 104]. Here, treatment-naive children with ADHD, but not 
those with a history of stimulant treatment, showed significant volume reductions compared 
to their typically developing peers. In a unique large-scale longitudinal study, Shaw et al. [99] 
found that over time, non-medicated adolescents with ADHD showed excessive cortical 
thinning compared to typically developing adolescents, whereas those who received stimulant 
medication did not. Again, other equally sized studies have reported null-findings i.e. no 
association between stimulant treatment and cortical thickness [105]. Summarizing, the 
literature on long-term stimulant treatment effects on brain structure is mixed, with several 
studies suggesting normalization, other reporting no brain changes after treatment, but no 
studies reporting detrimental effects. Future investigations may benefit from studying 
individual differences between patients, as illustrated by our study in which we found 
normalization of frontal cortex volume after stimulant treatment, but only in young carriers of 
the DRD4 7R-allele [101].  
 
Functional MRI (fMRI) studies have almost exclusively focused on the immediate rather than 
long-term effects of methylphenidate. In such studies, patients typically undergo scanning 
twice (once with and once without medication) while performing a cognitive task. A fairly 
consistent picture of acute stimulant effects emerges across various experimental designs. 
During cognitive control tasks, methylphenidate was found to normalize brain activation 
patterns by enhancing activation in fronto-striatal circuits [106, 107, 108, 109]. During tasks 
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tapping into attention, methylphenidate appeared to at least partially normalize brain 
activation and functional connectivity patterns in children with ADHD [110, 111] while at the 
same time eliciting non-normalizing, compensatory activation in the prefrontal cortex that 
was not evident in typically developing children [110]. Studies investigating acute stimulant 
effects during working memory tasks have yielded inconsistent results; whereas some 
suggested increased activity in frontal networks [112, 113], others reported reduced or 
unchanged frontal cortex activation patterns after methylphenidate administration [114, 115]. 
Finally, two resting-state fMRI studies suggested that methylphenidate might have an acute 
normalizing effect on striatal and cerebellar activation during rest [116, 117]. In sum, there is 
compelling evidence that a single dose of methylphenidate attenuates aberrant brain activation 
and functional connectivity patterns in children with ADHD, during tasks of cognitive control 
and attention as well as during rest. 
 
In contrast, potential long-term changes in brain function after stimulant treatment have 
received very little attention. To study lasting changes in brain activation patterns, patients 
with diverse treatment histories should be scanned while off medication. In a pharmacological 
MRI study, Schrantee et al. [118] found that after a one week wash-out period, children with 
ADHD who had received four months of stimulant treatment showed increased cerebral blood 
flow in response to a dopamine challenge, as compared to children who had received placebo. 
Conventional fMRI studies into long-term effects of treatment have all used cognitive tasks. 
During cognitive control, no difference was found in overall brain activation patterns between 
children who had received long-term treatment and those who had not, suggesting no lasting 
effect of treatment after wash-out [119, 120]. By contrast, brain activation patterns during 
reward processing were found to be associated with stimulant treatment history. Individuals 
with ADHD show reduced activation of the striatum in response to reward [121]. No such 
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reduction was found in adult patients with a history of childhood stimulant treatment [122]. A 
second study, however, found no evidence of normalized striatal activation patterns, but did 
find compensatory recruitment of the dorsal anterior cingulate cortex and supplementary 
motor area [123]. We conclude that there may be changes in brain activation patterns after 
childhood stimulant treatment that last after wash-out, but more studies are needed to confirm 
this. 
 
5. Drug- drug interactions 
 
Methylphenidate should not be used in patients being treated (currently or within the 
proceeding 2 weeks) with monoamine oxidase inhibitors. Because of possible increases in 
blood pressure, it should be used cautiously with vasopressor agents. Also, methylphenidate 
may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (e.g, phenobarbital, 
phenytoin, primidone), and some antidepressants (tricyclics and selective serotonin reuptake 
inhibitors) [124]. Downward dose adjustment of these drugs may be required when given 
concomitantly with methylphenidate.  
 
 
6. Expert opinion  
 
Stimulants such as methylphenidate are frequently being prescribed to children and 
adolescents because of ADHD. The short-term effects of methylphenidate in reducing the 
core ADHD symptom domains of hyperactivity, impulsivity, and inattention are well 
established. However, the same cannot be said about its long-term benefits, i.e., beyond a 
treatment duration of two years. For obvious ethical issues, high quality RCTs cannot be 
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performed to examine long-term effects of treatment. Evidence that is available at this point 
on long-term efficacy is derived from observational longitudinal studies, and come with its 
pitfalls. Also, the benefits of the drug on relevant functional outcomes such as academic 
achievement and the quality of peer relationships are less clear. Another concern is the 
growing use of stimulant treatment in ADHD. Most guidelines state that methylphenidate 
may only be considered as first line treatment in the case of severe ADHD, while in mild-to-
moderate ADHD the first line treatment should be behavioral interventions such as parent 
training. We doubt that such a severity distinction is routinely done in clinical practice, or that 
it is difficult for clinicians to make such distinctions. The subjective boundaries of a diagnosis 
of ADHD, forms a related problem in light of the growing use of stimulants in treating 
ADHD.  
 
With regard to the short-to-mid-term use (i.e., up to 2 years) stimulants are relatively safe. 
There appears to be no increased risk of cardiovascular death. However, mild adverse events 
do occur frequently; most notably decreased appetite and sleep disturbance, which can 
severely decrease quality of life, and should be monitored frequently. Recent meta-analyses 
indicate no risk of inducing or exacerbating tics, seizures, psychotic symptoms, substance 
misuse, or mood problems through stimulants. Well-conducted studies indicate that it is far 
more likely that ADHD in itself is associated with such symptoms rather than stimulant 
medication. Also, there is no indication of detrimental effects of stimulants on brain 
development. The safety situation on the longer term is much less well studied. This is a 
concern given that treatment duration of up to five years or longer is quite common in clinical 
practice, but hardly any high quality studies have been performed on this topic. Future studies 
should be aimed at longer-term outcomes, but also make use of higher detailed medication 
records instead of a mere yes/no variable. Especially the long-term cardiovascular safety 
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deserves better studies. A relatively unexplored area of research is that of sexual dysfunction 
following stimulant use. So far mainly case reports have been written on this topic [125] as 
initial reports are worrying, and larger scale studies are warranted in this area. A final 
important area for future studies would be to more systematically assess adverse effects of 
stimulants on cognition, motivation, and dampening of spontaneity/flat affect, mood 
dysregulation, and increased anxiety/edginess.  
 
Summarizing, some physical adverse events have been described (e.g. sleep disturbances, 
growth reduction, loss of appetite), although most are of transient nature. Psychiatric adverse 
events seem more related to the diagnosis ADHD itself, and not stimulant treatment. 
Concluding, short-to-mid-term use (i.e., up to 2 years) of stimulants is relatively safe, but 




- Mild adverse events occur frequently, most notably decreased appetite and sleep 
disturbance.   
- Adverse events can severely decrease quality of life, and should be monitored 
frequently. 
- Psychiatric adverse events, such as exacerbating tics, seizures, psychotic symptoms, 
substance misuse, or mood problems, seem primarily related to the diagnosis of 
ADHD itself, and not stimulant treatment.  
- Short-to-mid-term use (i.e., up to 2 years) of stimulants is relatively safe, but much 
less is known about longer-term efficacy and safety of these drugs, and longitudinal 
prospective studies are necessary. 
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- More research is warranted on adverse effects of stimulants on cognition, motivation, 
and dampening of spontaneity/flat affect, mood dysregulation, and increased 




1. American Psychiatric Association. Diagnostic and statistical manual of mental 
disorders [DSM-IV-TR]. Washington, DC: American Psychiatric Association; 2000. 
2. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual Research Review: 
A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. 
Journal of Child Psychology and Psychiatry. 2015;56:345-65. 
3. van Lieshout M, Luman M, Twisk JW, van Ewijk H, Groenman AP, Thissen AJ, 
Faraone SV, Heslenfeld DJ, Hartman CA, Hoekstra PJ, Franke B, Buitelaar JK, Rommelse 
NN, Oosterlaan J. A 6-year follow-up of a large European cohort of children with attention-
deficit/hyperactivity disorder-combined subtype: outcomes in late adolescence and young 
adulthood. European child & adolescent psychiatry. 2016;25:1007-17. Epub 2016/02/04. 
4. Simon V, Czobor P, Bálint S, Mészáros Á, Bitter I. Prevalence and correlates of adult 
attention-deficit hyperactivity disorder: meta-analysis. The British Journal of Psychiatry. 
2009;194:204-11. 
5. NICE. Attention Deficit Hyperactivity Disorder: Diagnosis and Management of 
ADHD in Children, Young People and Adults [Published: [NICE guideline]. 2008. Available 
from: http://www.nice.org.uk/CG72. 
6. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley 
SJ, Gifford A, Franceschi D. Therapeutic doses of oral methylphenidate significantly increase 
extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121. 
7. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Efficacy of 
methylphenidate, psychosocial treatments and their combination in school-aged children with 
ADHD: a meta-analysis. Clin Psychol Rev. 2008;28:783-800. 
8. Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity 
Disorder in Adolescents: A Systematic Review. Jama. 2016;315:1997-2008. Epub 
2016/05/11. 
9. Hinshaw SP, Arnold LE, M. T. A. Cooperative Group. Attention-deficit hyperactivity 
disorder, multimodal treatment, and longitudinal outcome: evidence, paradox, and challenge. 
Wiley Interdiscip Rev Cogn Sci. 2015;6:39-52. 
10. Cortese S, Brown TE, Corkum P, Gruber R, O'Brien LM, Stein M, Weiss M, Owens J. 
Assessment and management of sleep problems in youths with attention-deficit/hyperactivity 
disorder. J Am Acad Child Adolesc Psychiatry. 2013;52:784-96. Epub 2013/07/25. 
11. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and 
weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:994-1009. 
Epub 2008/06/27. 
12. Buitelaar JK, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Konofal E, 
Dejonckheere J, Challis BH, Medori R. Safety and tolerability of flexible dosages of 
prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity 
disorder. Neuropsychiatr Dis Treat. 2009;5:457-66. 
13. Storebo OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal 
S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi 
M, Kirubakaran R, Forsbol B, Simonsen E, Gluud C. Methylphenidate for children and 
adolescents with attention deficit hyperactivity disorder (ADHD). The Cochrane database of 
systematic reviews. 2015:Cd009885. Epub 2015/11/26. 
14. De Zegher F, Van Den Berghe G, Devlieger H, Eggermont E, Veldhuis JD. Dopamine 
inhibits growth hormone and prolactin secretion in the human newborn. Pediatric research. 
1993;34:642-5. 
15. Bereket A, Turan S, Karaman MG, Haklar G, Ozbay F, Yazgan MY. Height, weight, 
IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit 
 
 24 
hyperactivity disorder: effect of methylphenidate treatment. Hormone Research in Paediatrics. 
2005;63:159-64. 
16. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, 
Dopfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal 
E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, 
Steinhausen HC, Taylor E. European guidelines on managing adverse effects of medication 
for ADHD. Eur Child Adolesc Psychiatry. 2011;20:17-37. Epub 2010/11/03. 
17. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, 
Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BS, Hinshaw SP, Wells KC, 
Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron 
M, Volkow ND. Effects of stimulant medication on growth rates across 3 years in the MTA 
follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46:1015-27. 
18. Harstad E, Weaver AL, Katusic SK, Colligan RC, Kumar S, Chan E, Voigt RG, 
Barbaresi WJ. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics. 
2014;134:e935-44. Epub 2014/09/03. 
19. Satterfield JH, Cantwell DP, Schell A, Blaschke T. Growth of hyperactive children 
treated with methylphenidate. Archives of general psychiatry. 1979;36:212-7. 
20. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk 
of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical 
recommendations. J Am Acad Child Adolesc Psychiatry. 2011;50:978-90. Epub 2011/10/04. 
21. Antel J, Albayrak O, Heusch G, Banaschewski T, Hebebrand J. Assessment of 
potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need 
a SCOUT (trial)? European archives of psychiatry and clinical neuroscience. 2015;265:233-
47. Epub 2014/08/26. 
22. Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular 
problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 
2013;27:15-30. Epub 2012/11/20. 
23. Abbas S, Ihle P, Adler JB, Engel S, Gunster C, Linder R, Lehmkuhl G, Schubert I. 
Psychopharmacological Prescriptions in Children and Adolescents in Germany. Deutsches 
Arzteblatt international. 2016;113:396-403. Epub 2016/07/05. 
24. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood 
pressure associated with CNS stimulant treatment of ADHD in adults. Eur 
Neuropsychopharmacol. 2013;23:534-41. Epub 2012/07/17. 
25. Mazza M, D'Ascenzo F, Davico C, Biondi-Zoccai G, Frati G, Romagnoli E, Bassi B, 
Janiri L, Moretti C, Gaita F. Drugs for attention deficit-hyperactivity disorder do not increase 
the mid-term risk of sudden death in children: a meta-analysis of observational studies. 
International journal of cardiology. 2013;168:4320-1. Epub 2013/05/15. 
26. Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse 
cardiovascular events?: A systematic review. BMC cardiovascular disorders. 2012;12:41. 
Epub 2012/06/12. 
** This study provides an excellent systematic review of ten population-based observational 
studies of prescription stimulants and adverse cardiovascular events, as well as a critical 
discussion of methodological issues to be addressed in future research.   
 
27. Johnson MR. Fear of stimulant therapy for children and adolescents with attention-
deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology. 
2015;25:182. 
28. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, 
Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell 
 
 25 
FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. 
The New England journal of medicine. 2011;365:1896-904. Epub 2011/11/03. 
29. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham 
TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, 
Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. ADHD 
medications and risk of serious cardiovascular events in young and middle-aged adults. Jama. 
2011;306:2673-83. Epub 2011/12/14. 
30. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel 
GW, Cziraky MJ, Hennessy S. Cardiovascular events and death in children exposed and 
unexposed to ADHD agents. Pediatrics. 2011;127:1102-10. Epub 2011/05/18. 
31. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and 
atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug safety. 
2010;33:821-42. Epub 2010/09/04. 
32. Batra AS, Alexander ME, Silka MJ. Attention-deficit/hyperactivity disorder, stimulant 
therapy, and the patient with congenital heart disease: evidence and reason. Pediatric 
cardiology. 2012;33:394-401. Epub 2012/02/03. 
33. Winterstein AG. Cardiovascular safety of stimulants in children: findings from recent 
population-based cohort studies. Current psychiatry reports. 2013;15:379. Epub 2013/08/06. 
34. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, 
Cooper T. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 
2009;166:992-1001. Epub 2009/06/17. 
35. Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety 
of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide 
prospective cohort study. Journal of child and adolescent psychopharmacology. 2014;24:302-
10. Epub 2014/06/24. 
* This is the first nationwide prospective cohort study of the cardiovascular safety of 
stimulants in children and adolescents.  
 
36. Shin J-Y, Roughead EE, Park B-J, Pratt NL. Cardiovascular safety of methylphenidate 
among children and young people with attention-deficit/hyperactivity disorder (ADHD): 
nationwide self controlled case series study. The BMJ. 2016;353. 
37. Johnson MR. Increased cardiovascular risk associated with methylphenidate use in 
children and adolescents with ADHD? Examine the evidence. The BMJ. 2016;[letter to the 
editor]. 
38. Hammerness PG, Karampahtsis C, Babalola R, Alexander ME. Attention-
deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert 
opinion on drug safety. 2015;14:543-51. Epub 2015/02/05. 
** Provides an overview of long-term cardiovasular effects of stimulant use.  
 
 
39. Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, Molina BS, 
Wells K, Wigal T, Jensen PS, Greenhill LL, Kaltman JR, Severe JB, Odbert C, Hur K, 
Gibbons R. Blood pressure and heart rate over 10 years in the multimodal treatment study of 
children with ADHD. Am J Psychiatry. 2012;169:167-77. 
** A longitudinal study that examined the association between stimulant medication and 





40. Ravi M, Ickowicz A. Epilepsy, Attention-Deficit/Hyperactivity Disorder and 
Methylphenidate: Critical Examination of Guiding Evidence. J Can Acad Child Adolesc 
Psychiatry. 2016;25:50-8. 
41. Koneski JA, Casella EB. Attention deficit and hyperactivity disorder in people with 
epilepsy: diagnosis and implications to the treatment. Arq Neuropsiquiatr. 2010;68:107-14. 
42. Koneski JA, Casella EB, Agertt F, Ferreira MG. Efficacy and safety of 
methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled 
seizures: a Brazilian sample study and literature review. Epilepsy Behav. 2011;21:228-32. 
43. Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman 
JF, Bloch MH. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in 
Randomized, Placebo-Controlled Trials. J Am Acad Child Adolesc Psychiatry. 2015;54:728-
36. 
44. Golden GS. Gilles de la Tourette's syndrome following methylphenidate 
administration. Dev Med Child Neurol. 1974;16:76-8. 
45. Pollack MA, Cohen NL, Friedhoff AJ. Gilles de la Tourette's syndrome. Familial 
occurrence and precipitation by methylphenidate therapy. Arch Neurol. 1977;34:630-2. 
46. Bremness AB, Sverd J. Methylphenidate-induced Tourette syndrome: case report. Am 
J Psychiatry. 1979;136:1334-5. 
47. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant 
medications precipitate Tourette's syndrome. Jama. 1982;247:1729-31. 
48. Fras I, Karlavage J. The use of methylphenidate and imipramine in Gilles de la 
Tourette's disease in children. Am J Psychiatry. 1977;134:195-7. 
49. Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate 
administration. A report of 20 cases. Jama. 1976;235:1349-51. 
50. Shapiro AK, Shapiro E. Do stimulants provoke, cause, or exacerbate tics and Tourette 
syndrome? Compr Psychiatry. 1981;22:265-73. 
51. Gadow KD, Nolan E, Sprafkin J, Sverd J. School observations of children with 
attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate 
treatment. J Dev Behav Pediatr. 1995;16:167-76. 
52. Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid 
tic disorder: II. Short-term behavioral effects in school settings. J Am Acad Child Adolesc 
Psychiatry. 1992;31:462-71. 
53. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate 
therapy in children with comorbid attention-deficit hyperactivity disorder and chronic 
multiple tic disorder. Arch Gen Psychiatry. 1999;56:330-6. 
54. Price RA, Leckman JF, Pauls DL, Cohen DJ, Kidd KK. Gilles de la Tourette's 
syndrome: tics and central nervous system stimulants in twins and nontwins. Neurology. 
1986;36:232-7. 
55. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport 
JL. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of 
stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36:589-96. 
56. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in 
children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc 
Psychiatry. 1999;38:944-51. 
57. Tourette syndrome study group. Treatment of ADHD in children with tics: a 
randomized controlled trial. Neurology. 2002;58:527-36. Epub 2002/02/28. 
58. Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV. Emergence of tics in 
children with ADHD: impact of once-daily OROS methylphenidate therapy. Journal of child 
and adolescent psychopharmacology. 2004;14:185-94. 
 
 27 
59. Kraemer M, Uekermann J, Wiltfang J, Kis B. Methylphenidate-induced psychosis in 
adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the 
literature. Clin Neuropharmacol. 2010;33:204-6. 
60. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention 
deficit hyperactivity disorder. Am J Psychiatry. 2006;163:1149-52. 
61. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. 
Can J Psychiatry. 1999;44:811-3. 
62. MacKenzie LE, Abidi S, Fisher HL, Propper L, Bagnell A, Morash-Conway J, Glover 
JM, Cumby J, Hajek T, Schultze-Lutter F, Pajer K, Alda M, Uher R. Stimulant Medication 
and Psychotic Symptoms in Offspring of Parents With Mental Illness. Pediatrics. 2016;137. 
63. Moran LV, Masters GA, Pingali S, Cohen BM, Liebson E, Rajarethinam RP, Ongur 
D. Prescription stimulant use is associated with earlier onset of psychosis. J Psychiatr Res. 
2015;71:41-7. 
64. Shyu YC, Yuan SS, Lee SY, Yang CJ, Yang KC, Lee TL, Wang LJ. Attention-
deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia 
spectrum disorders: A nationwide population-based study in Taiwan. Schizophr Res. 
2015;168:161-7. 
65. Man KK, Coghill D, Chan EW, Lau WC, Hollis C, Liddle E, Banaschewski T, 
McCarthy S, Neubert A, Sayal K, Ip P, Wong IC. Methylphenidate and the risk of psychotic 
disorders and hallucinations in children and adolescents in a large health system. Transl 
Psychiatry. 2016;6:e956. 
66. Dalsgaard S, Mortensen PB, Frydenberg M, Maibing CM, Nordentoft M, Thomsen 
PH. Association between Attention-Deficit Hyperactivity Disorder in childhood and 
schizophrenia later in adulthood. Eur Psychiatry. 2014;29:259-63. 
67. Lee, Yang KC, Shyu YC, Yuan SS, Yang CJ, Lee SY, Lee TL, Wang LJ. Attention-
deficit hyperactivity disorder, its treatment with medication and the probability of developing 
a depressive disorder: A nationwide population-based study in Taiwan. J Affect Disord. 
2016;189:110-7. 
68. Wang LJ, Shyu YC, Yuan SS, Yang CJ, Yang KC, Lee TL, Lee SY. Attention-deficit 
hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A 
nationwide population-based study in Taiwan. J Psychiatr Res. 2016;72:6-14. 
69. Hegerl U, Sander C, Olbrich S, Schoenknecht P. Are psychostimulants a treatment 
option in mania? Pharmacopsychiatry. 2009;42:169-74. 
70. Gurkan K, Bilgic A, Turkoglu S, Kilic BG, Aysev A, Uslu R. Depression, anxiety and 
obsessive-compulsive symptoms and quality of life in children with attention-deficit 
hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J 
Psychopharmacol. 2010;24:1810-8. 
71. Chen Q, Sjolander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H. Drug 
treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based 
study. The BMJ. 2014;348:g3769. 
72. Kovshoff H, Banaschewski T, Buitelaar JK, Carucci S, Coghill D, Danckaerts M, 
Dittmann RW, Falissard B, Grimshaw DG, Hollis C, Inglis S, Konrad K, Liddle E, McCarthy 
S, Nagy P, Thompson M, Wong IC, Zuddas A, Sonuga-Barke EJ. Reports of Perceived 
Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative 
Investigation and the Generation of Items for the Medication and Cognition Rating Scale. 
Journal of child and adolescent psychopharmacology. 2016;26:537-47. 
73. Charach A, Yeung E, Climans T, Lillie E. Childhood Attention-Deficit/Hyperactivity 
Disorder and Future Substance Use Disorders: Comparative Meta-Analyses. Journal of the 
American Academy of Child and Adolescent Psychiatry. 2011;50:9-21. 
 
 28 
74. Goldman LS, Genel M, Bezman RJ, Slanetz PJ, Assoc AM. Diagnosis and treatment 
of attention-deficit/hyperactivity disorder in children and adolescents. Jama-J Am Med Assoc. 
1998;279:1100-7. 
75. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance 
dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 
1998;31:533-44. 
76. Schoenfelder EN, Faraone SV, Kollins SH. Stimulant treatment of ADHD and 
cigarette smoking: a meta-analysis. Pediatrics. 2014;133:1070-80. Epub 2014/05/14. 
* One of two recent meta analysis looking at the effect of stimulant treatment on the 
development of smoking in ADHD 
 
 
77. Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a 
meta-analysis. JAMA Psychiatry. 2013;70:740-9. Epub 2013/06/12. 
* One of two recent meta analysis looking at the effect of stimulant treatment on the 
development of substance use disorders in ADHD 
 
78. Groenman AP, Oosterlaan J, Rommelse NN, Franke B, Greven CU, Hoekstra PJ, 
Hartman CA, Luman M, Roeyers H, Oades RD, Sergeant JA, Buitelaar JK, Faraone SV. 
Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing 
substance use disorder. The British journal of psychiatry : the journal of mental science. 
2013;203:112-9. Epub 2013/07/13. 
79. McCabe SE, Dickinson K, West BT, Wilens TE. Age of Onset, Duration, and Type of 
Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During 
Adolescence: A Multi-Cohort National Study. J Am Acad Child Adolesc Psychiatry. 
2016;55:479-86. 
** Excellent national cohort study looking at characteristics of stimulant use on the 
development of substance use in ADHD.  
 
80. Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-
deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year 
prospective study. Pediatrics. 2003;111:97-109. 
81. Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, 
Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, 
Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S. Adolescent Substance Use in 
the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) 
(MTA) as a Function of Childhood ADHD, Random Assignment to Childhood Treatments, 
and Subsequent Medication. Journal of the American Academy of Child and Adolescent 
Psychiatry. 2013;52:250-63. Epub 2013/03/05. 
82. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle 
CL, Swets M, Schoevers RA. Prevalence of attention-deficit hyperactivity disorder in 
substance use disorder patients: a meta-analysis and meta-regression analysis. Drug and 
alcohol dependence. 2012;122:11-9. Epub 2012/01/03. 
*Meta-analysis looking at the prevalence of ADHD in a substance use disorder population 
 
83. Harstad E, Levy S. Attention-deficit/hyperactivity disorder and substance abuse. 
Pediatrics. 2014;134:e293-e301. 
84. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we 




85. Cunill R, Castells X, Tobias A, Capellà D. Pharmacological treatment of attention 
deficit hyperactivity disorder with co-morbid drug dependence. Journal of 
psychopharmacology. 2015;29:15-23. 
86. Barkla XM, McArdle PA, Newbury-Birch D. Are there any potentially dangerous 
pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A 
systematic review of the literature. BMC Psychiatry. 2015;15:270. 
87. Garbarino S, Lanteri P, Durando P, Magnavita N, Sannita WG. Co-Morbidity, 
Mortality, Quality of Life and the Healthcare/Welfare/Social Costs of Disordered Sleep: A 
Rapid Review. International Journal of Environmental Research and Public Health. 
2016;13:831. 
88. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep medicine. 
2010;11:652-8. Epub 2010/07/14. 
** A critical overview of studies on ADHD and sleep.  
 
89. Becker SP, Langberg JM, Evans SW. Sleep problems predict comorbid externalizing 
behaviors and depression in young adolescents with attention-deficit/hyperactivity disorder. 
European child & adolescent psychiatry. 2015;24:897-907. Epub 2014/11/02. 
90. Arns M, van der Heijden KB, Arnold LE, Kenemans JL. Geographic variation in the 
prevalence of attention-deficit/hyperactivity disorder: the sunny perspective. Biological 
psychiatry. 2013;74:585-90. Epub 2013/03/26. 
91. Kidwell KM, Van Dyk TR, Lundahl A, Nelson TD. Stimulant Medications and Sleep 
for Youth With ADHD: A Meta-analysis. Pediatrics. 2015:peds. 2015-1708. 
92. Santisteban JA, Stein MA, Bergmame L, Gruber R. Effect of Extended-Release 
Dexmethylphenidate and Mixed Amphetamine Salts on Sleep: A Double-Blind, Randomized, 
Crossover Study in Youth with Attention-Deficit Hyperactivity Disorder. CNS drugs. 
2014;28:825-33. 
93. Hiscock H, Sciberras E, Mensah F, Gerner B, Efron D, Khano S, Oberklaid F. Impact 
of a behavioural sleep intervention on symptoms and sleep in children with attention deficit 
hyperactivity disorder, and parental mental health: randomised controlled trial. The BMJ. 
2015;350. 
94. Frodl T, Skokauskas N. Meta-analysis of structural MRI studies in children and adults 
with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr Scand. 
2012;125:114-26. 
** One of two influential meta-analyses reporting brain changes in individuals with ADHD 
are more promounced in studies that included mostly treatment-naïve patients. 
 
95. Nakao T, Radua J, Rubia K, Mataix-Cols D. Gray matter volume abnormalities in 
ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am 
J Psychiatry. 2011;168:1154-63. 
** One of two influential meta-analyses reporting brain changes in individuals with ADHD 
are more promounced in studies that included mostly treatment-naïve patients. 
 
96. Greven CU, Bralten J, Mennes M, O'Dwyer L, van Hulzen KJ, Rommelse N, 
Schweren LJ, Hoekstra PJ, Hartman CA, Heslenfeld D, Oosterlaan J, Faraone SV, Franke B, 
Zwiers MP, Arias-Vasquez A, Buitelaar JK. Developmentally stable whole-brain volume 
reductions and developmentally sensitive caudate and putamen volume alterations in those 




97. Onnink AM, Zwiers MP, Hoogman M, Mostert JC, Kan CC, Buitelaar J, Franke B. 
Brain alterations in adult ADHD: effects of gender, treatment and comorbid depression. Eur 
Neuropsychopharmacol. 2014;24:397-409. 
98. Semrud-Clikeman M, Pliszka SR, Bledsoe J, Lancaster J. Volumetric MRI differences 
in treatment naive and chronically treated adolescents with ADHD-combined type. J Atten 
Disord. 2014;18:511-20. 
99. Shaw P, Sharp WS, Morrison M, Eckstrand K, Greenstein DK, Clasen LS, Evans AC, 
Rapoport JL. Psychostimulant treatment and the developing cortex in attention deficit 
hyperactivity disorder. Am J Psychiatry. 2009;166:58-63. 
** A unique large-scale longitudinal study on long-term brain changes after stimulant 
treatment 
 
100. Hoekzema E, Carmona S, Ramos-Quiroga JA, Richarte Fernandez V, Picado M, 
Bosch R, Soliva JC, Rovira M, Vives Y, Bulbena A, Tobena A, Casas M, Vilarroya O. 
Laminar thickness alterations in the fronto-parietal cortical mantle of patients with attention-
deficit/hyperactivity disorder. PLoS One. 2012;7:e48286. 
101. Schweren LJ, Hartman CA, Heslenfeld DJ, Groenman AP, Franke B, Oosterlaan J, 
Buitelaar JK, Hoekstra PJ. Age and DRD4 Genotype Moderate Associations Between 
Stimulant Treatment History and Cortex Structure in Attention-Deficit/Hyperactivity 
Disorder. J Am Acad Child Adolesc Psychiatry. 2016;55:877-85 e3. 
* Large-scale study in adolescents with ADHD finds no evidence of brain changes associated 
with stimulant treatment history 
 
102. Bledsoe J, Semrud-Clikeman M, Pliszka SR. A magnetic resonance imaging study of 
the cerebellar vermis in chronically treated and treatment-naive children with attention-
deficit/hyperactivity disorder combined type. Biological psychiatry. 2009;65:620-4. 
103. Ivanov I, Bansal R, Hao X, Zhu H, Kellendonk C, Miller L, Sanchez-Pena J, Miller 
AM, Chakravarty MM, Klahr K, Durkin K, Greenhill LL, Peterson BS. Morphological 
abnormalities of the thalamus in youths with attention deficit hyperactivity disorder. Am J 
Psychiatry. 2010;167:397-408. 
104. Semrud-Clikeman M, Pliszka SR, Lancaster J, Liotti M. Volumetric MRI differences 
in treatment-naive vs chronically treated children with ADHD. Neurology. 2006;67:1023-7. 
105. Schweren LJ, Hartman CA, Heslenfeld DJ, van der Meer D, Franke B, Oosterlaan J, 
Buitelaar JK, Faraone SV, Hoekstra PJ. Thinner Medial Temporal Cortex in Adolescents 
With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants. J Am Acad 
Child Adolesc Psychiatry. 2015;54:660-7. 
106. Epstein JN, Casey BJ, Tonev ST, Davidson MC, Reiss AL, Garrett A, Hinshaw SP, 
Greenhill LL, Glover G, Shafritz KM, Vitolo A, Kotler LA, Jarrett MA, Spicer J. ADHD- and 
medication-related brain activation effects in concordantly affected parent-child dyads with 
ADHD. J Child Psychol Psychiatry. 2007;48:899-913. 
107. Lee YS, Han DH, Lee JH, Choi TY. The Effects of Methylphenidate on Neural 
Substrates Associated with Interference Suppression in Children with ADHD: A Preliminary 
Study Using Event Related fMRI. Psychiatry Investig. 2010;7:49-54. 
108. Rubia K, Halari R, Mohammad AM, Taylor E, Brammer M. Methylphenidate 
normalizes frontocingulate underactivation during error processing in attention-
deficit/hyperactivity disorder. Biological psychiatry. 2011;70:255-62. 
109. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, 
Gabrieli JD. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a 
functional magnetic resonance study. Proc Natl Acad Sci U S A. 1998;95:14494-9. 
 
 31 
110. Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E. 
Methylphenidate normalises activation and functional connectivity deficits in attention and 
motivation networks in medication-naive children with ADHD during a rewarded continuous 
performance task. Neuropharmacology. 2009;57:640-52. 
111. Shafritz KM, Marchione KE, Gore JC, Shaywitz SE, Shaywitz BA. The effects of 
methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Am 
J Psychiatry. 2004;161:1990-7. 
112. Prehn-Kristensen A, Krauel K, Hinrichs H, Fischer J, Malecki U, Schuetze H, Wolff 
S, Jansen O, Duezel E, Baving L. Methylphenidate does not improve interference control 
during a working memory task in young patients with attention-deficit hyperactivity disorder. 
Brain Res. 2011;1388:56-68. 
113. Wong CG, Stevens MC. The effects of stimulant medication on working memory 
functional connectivity in attention-deficit/hyperactivity disorder. Biological psychiatry. 
2012;71:458-66. 
114. Sheridan MA, Hinshaw S, D'Esposito M. Stimulant medication and prefrontal 
functional connectivity during working memory in ADHD: a preliminary report. J Atten 
Disord. 2010;14:69-78. 
115. Kobel M, Bechtel N, Weber P, Specht K, Klarhofer M, Scheffler K, Opwis K, Penner 
IK. Effects of methylphenidate on working memory functioning in children with attention 
deficit/hyperactivity disorder. Eur J Paediatr Neurol. 2009;13:516-23. 
116. Anderson CM, Polcari A, Lowen SB, Renshaw PF, Teicher MH. Effects of 
methylphenidate on functional magnetic resonance relaxometry of the cerebellar vermis in 
boys with ADHD. Am J Psychiatry. 2002;159:1322-8. 
117. Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF. Functional 
deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with 
functional magnetic resonance imaging relaxometry. Nat Med. 2000;6:470-3. 
118. Schrantee A, Tamminga HG, Bouziane C, Bottelier MA, Bron EE, Mutsaerts HJ, 
Zwinderman AH, Groote IR, Rombouts SA, Lindauer RJ, Klein S, Niessen WJ, Opmeer BC, 
Boer F, Lucassen PJ, Andersen SL, Geurts HM, Reneman L. Age-Dependent Effects of 
Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With 
Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 
2016;73:955-62. 
* Elegantly designed study showing that stimulant treatment may have a more lasting impact 
on younger as compared to older brains 
 
119. Pliszka SR, Glahn DC, Semrud-Clikeman M, Franklin C, Perez R, 3rd, Xiong J, Liotti 
M. Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity 
disorder who were treatment naive or in long-term treatment. Am J Psychiatry. 
2006;163:1052-60. 
120. Konrad K, Neufang S, Fink GR, Herpertz-Dahlmann B. Long-term effects of 
methylphenidate on neural networks associated with executive attention in children with 
ADHD: results from a longitudinal functional MRI study. J Am Acad Child Adolesc 
Psychiatry. 2007;46:1633-41. 
121. von Rhein D, Cools R, Zwiers MP, van der Schaaf M, Franke B, Luman M, 
Oosterlaan J, Heslenfeld DJ, Hoekstra PJ, Hartman CA, Faraone SV, van Rooij D, van 
Dongen EV, Lojowska M, Mennes M, Buitelaar J. Increased neural responses to reward in 
adolescents and young adults with attention-deficit/hyperactivity disorder and their unaffected 
siblings. J Am Acad Child Adolesc Psychiatry. 2015;54:394-402. 
122. Stoy M, Schlagenhauf F, Schlochtermeier L, Wrase J, Knutson B, Lehmkuhl U, Huss 
M, Heinz A, Strohle A. Reward processing in male adults with childhood ADHD--a 
 
 32 
comparison between drug-naive and methylphenidate-treated subjects. Psychopharmacology 
(Berl). 2011;215:467-81. 
123. Schweren LJ, Groenman AP, von Rhein D, Weeda W, Faraone S, Luman M, van 
Ewijk H, Heslenfeld D, Franke B, Buitelaar JK, Oosterlaan J, Hoekstra PJ, Hartman CA. 
Stimulant treatment trajectories are associated with neural reward processing in attention-
deficit/hyperactivity disorder. Journal of Clinical Psychiatry. In Press. 
124. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions 
in the treatment of attention-deficit hyperactivity disorder. Clinical pharmacokinetics. 
2001;40:753-72. Epub 2001/11/15. 
125. Eiland LS, Bell EA, Erramouspe J. Priapism associated with the use of stimulant 
medications and atomoxetine for attention-deficit/hyperactivity disorder in children. The 
Annals of pharmacotherapy. 2014;48:1350-5. Epub 2014/07/02. 
 
